News
AVATAR MEDICAL raises €1.2 million for its virtual reality medical imaging solution for Surgeons
Partnership agreement between the Calym Carnot Institute and IQVIA
LETI INNOVATION DAYS - reported October 12-16 in Grenoble.
CES 2020 : Interview Valery Cervantes Esprit Project Coordinator - Carnot Energies du futur
CES 2020: Interview Sophie Morales LSIV Lab manager - Carnot Leti
CES 2020: Interview Lionel Rudant Founder & CTO - Anteneo - Carnot Leti
CES 2020: Interview Dimitri Ktenas Head of Wireless Technologie - Carnot Leti
Chimie Balard Cirimat Carnot Institute at European Utility Week in Paris
Novel antibiotics: DEINOVE signs an agreement with the Institut Pasteur (Pasteur MS Carnot Institute) to explore the potential of new targeted strains
DEINOVE, a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-based active ingredients for cosmetics and nutrition, has announced that it will benefit from the Institut Pasteur's provision of biological resources for the research of new antimicrobial agents from original strains. The Institut Pasteur (Pasteur MS Carnot Institute), one of the most renowned worldwide players in the area of infectious disease research, will entrust a targeted selection of strains from their bacterial collection to DEINOVE.
International Industries Forum about Innovative Bio-Based Materials
The Leti Carnot Institute at SEMICON Europa 2016 in Grenoble
The Leti Carnot Institute will exhibit at SEMICON Europa 2016 in Grenoble, France, on Oct 25-27.
Learn more about the latest advancements in microelectronics with Leti experts as they discuss through a selection of conferences, forums and sessions.
Register now to download the full program and make the most of the largest microelectronics event in Europe!
CALYM’S 3rd SCIENTIFIC & PARTNERING DAY
CALYM’s 3rd SCIENTIFIC & PARTNERING DAY, will take place next October 17, 2016 in Paris, Espace Van Gogh, 62, quai de la Rapée.
CALYM researchers and clinicians will be happy to present the new lymphoma R&D offering and highlight research results of the consortium, from new therapeutic targets identification to Phase III pivotal clinical trials and beyond.
IPSEN and CELGENE representatives will bring industry standpoint.